Article
Engineering, Biomedical
Ting Zhao, Rongping Zhang, Qin He, Hongli Zhou, Xu Song, Tao Gong, Zhirong Zhang
Summary: This study established a CAF-targeting drug delivery system based on RBC vesicles partial protection for reprogramming the tumor microenvironment and enhancing tumor penetration and antitumor efficacy in PDAC. The results showed that the system improved the penetration of Dox in PDAC and inhibited tumor growth.
ACTA BIOMATERIALIA
(2022)
Article
Immunology
Azaz Ahmed, Rosa Klotz, Sophia Koehler, Nathalia Giese, Thilo Hackert, Christoph Springfeld, Dirk Jaeger, Niels Halama
Summary: This study investigated the immune features of the stroma in PDA patients, revealing a significant association of IL9 and IL18 with patient survival outcomes. IL9 was linked to an anti-tumoral cytokine network, while IL18 was associated with exhausted T cells. Patients with PDA showed higher serum levels of IL9 and lower levels of IL18 compared to healthy controls.
FRONTIERS IN IMMUNOLOGY
(2022)
Editorial Material
Biology
Jessica Castrillon Lal
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a low survival rate. Understanding the complexity of tumor architecture and identifying targetable cellular phenotypes are major challenges in PDAC. Recent research has found recurrent gene expression patterns in malignant and fibroblast cellular neighborhoods in PDAC tumors that are correlated with treatment outcomes.
COMMUNICATIONS BIOLOGY
(2022)
Review
Oncology
Vida Karimnia, Frank J. Slack, Jonathan P. Celli
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with current clinical trials showing limited improvements in patient survival. Photodynamic therapy (PDT) has emerged as a potential approach for treating pancreatic tumors based on studies indicating its effectiveness in activating photosensitizing agents in target tissues.
Review
Cell Biology
Tianyi Zhang, Yanxian Ren, Pengfei Yang, Jufang Wang, Heng Zhou
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a high deposition of extracellular matrix (ECM) and poor prognosis. ECM proteins derived from tumor cells reduce the effectiveness of conventional cancer treatment and contribute to tumor progression and metastasis. Cancer-associated fibroblasts (CAFs) in the ECM are promising targets for novel anti-tumor interventions.
CELL DEATH & DISEASE
(2022)
Review
Biochemistry & Molecular Biology
Utpreksha Vaish, Tejeshwar Jain, Abhi C. Are, Vikas Dudeja
Summary: PDAC is a major cause of cancer-related mortality in the western world, with CAFs playing a key role in the tumor microenvironment and being potential targets for therapy. However, there is significant heterogeneity in CAFs within PDAC, highlighting the importance of understanding and delineating this heterogeneity before targeting them for treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Nicole Lintern, Andrew M. Smith, David G. Jayne, Yazan S. Khaled
Summary: Pancreatic cancer is highly lethal with low survival rate. The resistance to current therapies is largely attributed to the dense tissue surrounding the cancer cells. Photodynamic therapy (PDT) has shown potential in killing pancreatic cancer cells and altering the surrounding tissue.
Article
Medicine, General & Internal
Kai Chen, Qi Wang, Mingzhe Li, Huahu Guo, Weikang Liu, Feng Wang, Xiaodong Tian, Yinmo Yang
Summary: This study utilized single-cell RNA sequencing to explore the dynamic changes of tumor microenvironment components during PDAC malignant progression, revealing gradual accumulation of immune cells and pancreatic stellate cells. New Treg and exhausted T cell signature genes were identified, and patients with high expression of certain genes had significantly worse prognosis. A new subset of CAFs specific to PDAC, csCAFs, was also discovered.
Review
Gastroenterology & Hepatology
Thomas Lambin, Cyril Lafon, Robert Andrew Drainville, Mathieu Pioche, Frederic Prat
Summary: Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of death from cancer by 2030. The tumoral microenvironment (TME) of PDAC, characterized by fibrosis, hypo microvascular perfusion, and immunosuppression, is a major barrier to effective antitumoral treatment. Locoregional therapies, such as radiofrequency ablation and radiation therapy, hold promise for overcoming these barriers and improving clinical outcomes for PDAC patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Oncology
Taija Korpela, Ari Ristimaki, Marianne Udd, Tiina Vuorela, Harri Mustonen, Caj Haglund, Leena Kylanpaa, Hanna Seppanen
Summary: This study investigated the potential role of histological chronic pancreatitis findings and chronic inflammation in surgical pancreatic ductal adenocarcinoma (PDAC) specimens on disease-specific survival (DSS). The results suggest that more severe fibrosis, acinar atrophy, and chronic inflammation in the pancreatic stroma were associated with worse DSS outcomes for PDAC patients.
Article
Oncology
Shaofei Liu, Yasir Suhail, Ashkan Novin, Lorrie Perpetua, Kshitiz
Summary: This study examines the diversity of fibroblasts in different stages of Pancreatic Ductal Cell Adenocarcinoma (PDAC) metastasis. It finds that the function of fibroblasts undergoes significant changes as cancer progresses, transitioning from resisting cancer invasion to promoting cancer dissemination. These findings contribute to a better understanding of the role of stromal cells in cancer metastasis.
Review
Immunology
Sophie Liot, Jonathan Balas, Alexandre Aubert, Laura Prigent, Perrine Mercier-Gouy, Bernard Verrier, Philippe Bertolino, Ana Hennino, Ulrich Valcourt, Elise Lambert
Summary: Pancreatic cancer, especially PDAC, has a poor prognosis with low survival rates, mainly due to its dense stroma deposition and immune suppression in the TME. Research on TME composition may lead to new therapeutic targets for better treatment outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Yu Wang, Yiyi Liang, Haiyan Xu, Xiao Zhang, Tiebo Mao, Jiujie Cui, Jiayu Yao, Yongchao Wang, Feng Jiao, Xiuying Xiao, Jiong Hu, Qing Xia, Xiaofei Zhang, Xujun Wang, Yongwei Sun, Deliang Fu, Lei Shen, Xiaojiang Xu, Jing Xue, Liwei Wang
Summary: The study investigated the heterogeneity among PDAC patients in terms of CAFs, ductal cancer cells, and immune cells, revealing differences between dense-type and loose-type PDAC. A novel subtype of CAFs, meCAFs, was discovered in loose-type PDAC, playing a critical role in disease progression and response to immunotherapy. This finding highlights the importance of considering intertumoral heterogeneity in PDAC treatment strategies.
Review
Oncology
Nebojsa Skorupan, Mayrel Palestino Dominguez, Samuel L. Ricci, Christine Alewine
Summary: This review discusses the diverse cell composition and interactions in pancreatic cancer tumors, as well as the impact on cancer cell growth and treatment responses. It also introduces new drug therapies and clinical trials.
Review
Medicine, Research & Experimental
Alla Kuznetsova, Olga Popova, Dmitry Panchenkov, Tatyana Dyuzheva, Alexey Ivanov
Summary: Diagnosis and treatment of carcinoma of the exocrine part of the pancreas is a serious problem. The tumor microenvironment (TME) plays an important role in tumor progression, but the mechanisms underlying the effect of cancer-associated fibroblasts (CAFs) and extracellular matrix (ECM) are still unclear. Recent studies provide optimism for the development of targeted therapies for pancreatic ductal adenocarcinoma (PDAC).
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)